Methodology · Reviewed Q2 2026

Three mechanisms.
Six actives.

The publication is composed of six actives, addressing three distinct biological mechanisms in benign prostatic hyperplasia. The published literature behind each mechanism is reviewed below. The trial base is, as the editorial board has noted elsewhere, uneven; the picture is set out here in the form the literature actually supports.

Mechanism I · On 5-alpha-reductase

I.On the modulation of DHT in prostate tissue.

Lifetime DHT exposure is the primary driver of benign prostatic hyperplasia. The men who happen to be genetically deficient in 5-alpha-reductase — the enzyme that converts testosterone to DHT — almost never develop BPH or male-pattern baldness.1 So the obvious therapeutic target is to modulate DHT modestly within prostate tissue, without disrupting systemic testosterone.

This is what Saw Palmetto’s lipidosterolic extract does. The fatty acids and plant sterols weakly inhibit 5-alpha-reductase activity in prostate tissue specifically — far less potently than prescription drugs like finasteride, but with a dramatically milder side-effect profile.2

Reference

Wilt et al., 1998 — Cochrane review of eighteen randomised trials of Saw Palmetto in BPH. Modest but consistent improvements in IPSS scores and urinary flow rates over six- to twelve-month courses at 320 mg per day of standardised lipidosterolic extract.

Mechanism II · On complementary pathways

II.On complementary anti-inflammatory and tissue-support pathways.

Beta-Sitosterol and Pygeum bring complementary mechanisms beyond DHT modulation. Beta-Sitosterol affects urinary flow rate and bladder emptying via different cellular pathways.3 Pygeum reduces tissue inflammation and has independent evidence for reducing nocturia frequency.4

Stinging Nettle root provides additional adjunctive support, particularly via lignan binding to SHBG.5 The combination is synergistic — each ingredient addresses a slightly different aspect of the same overall pattern.

Reference

Wilt et al., 2002 — Pygeum review showing modest improvements in nocturia, peak urine flow, and residual urinary volume across eighteen controlled trials. Standardisation across commercial extracts varies considerably and accounts for some inter-trial variance.

Mechanism III · On the two deficiencies

III.On the closing of two near-universal deficiencies.

The prostate has the highest zinc concentration of any tissue in the male body. Zinc is structurally required for the testosterone synthesis machinery in the testes and for healthy prostate tissue function.6 Vitamin D receptors sit directly on prostate tissue, and adequate D3 status is associated with better prostate biomarkers in observational data.7

Roughly a third of EU men over fifty are zinc-deficient. Wintertime Vitamin D3 deficiency in northern European men runs above sixty per cent.8 Closing these gaps is one of the highest-leverage components of any midlife men’s health intervention — and it is done at a cost of a few cents per dose.

  1. Imperato-McGinley J. N Engl J Med. 1979;300:1233–1237. Pseudohermaphroditism and 5-AR deficiency.
  2. Plosker GL, Brogden RN. Drugs & Aging. 1996;9(5):379–395. Serenoa repens pharmacology.
  3. Berges RR, et al. Lancet. 1995;345:1529–1532. Beta-sitosterol in BPH.
  4. Wilt TJ, et al. Cochrane Database Syst Rev. 2002;(1). Pygeum africanum.
  5. Schneider T, Rübben H. Urologe A. 2004;43:302–306. Urtica dioica lignans.
  6. Costello LC, Franklin RB. Prostate. 1998;35(4):285–296. Zinc and prostate function.
  7. Pilz S, et al. Clin Endocrinol. 2011;75(5):575–584. Vitamin D and prostate biomarkers.
  8. Holick MF. N Engl J Med. 2007;357:266–281. Vitamin D deficiency.
Editorial caveats · Reviewed Q2 2026

On what the publication is not.

Caveat · I

Not a substitute for medical care.

If you have severe BPH symptoms, ProstaRemedy is not equivalent to prescription alpha-blockers or 5-ARI medications. Speak to your urologist about appropriate medical management.

Caveat · II

Not a fast-acting product.

Saw Palmetto and Pygeum take four to twelve weeks to express their full effects. If you are taking it for two weeks, that is not the protocol.

Caveat · III

Not for everyone.

If you are under 30, on prescription endocrine medication, on anti-coagulants, or have a history of hormone-sensitive conditions — speak to your doctor before starting.

Caveat · IV

Not a cancer treatment or screening tool.

Continue with your doctor-recommended PSA monitoring and DRE schedule. ProstaRemedy supports prostate function; it does not detect or treat prostate cancer.

On subscribing

Subscribe for sixty days. Returned without question.

Distribution included. The bottle is not required to be returned.

60-day subscription — $180